Insulet hires Convatec, Eli Lilly alum as new R&D chief Read more →

Eli Lilly reunites with Abbisko in $1.9B, multiple target R&D pact Read more →

Ollin hauls in $330M to enlist Vabysmo challenger in phase 3 eye disease gauntlet Read more →